JP2007520507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520507A5 JP2007520507A5 JP2006551762A JP2006551762A JP2007520507A5 JP 2007520507 A5 JP2007520507 A5 JP 2007520507A5 JP 2006551762 A JP2006551762 A JP 2006551762A JP 2006551762 A JP2006551762 A JP 2006551762A JP 2007520507 A5 JP2007520507 A5 JP 2007520507A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- physiologically acceptable
- inhibitor
- glycopyrrolate
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 9
- 101710031992 pRL90232 Proteins 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 101710035540 plaa2 Proteins 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 229940015042 Glycopyrrolate Drugs 0.000 claims 4
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 4
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 4
- 208000006673 Asthma Diseases 0.000 claims 3
- 206010038683 Respiratory disease Diseases 0.000 claims 3
- MNDBXUUTURYVHR-UHFFFAOYSA-N Roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims 3
- 229960002586 Roflumilast Drugs 0.000 claims 3
- 230000000699 topical Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N N-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 1
- 229950005741 rolipram Drugs 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Claims (17)
- 気管支喘息及び慢性閉塞性肺疾患(ＣＯＰＤ)を含む呼吸器系疾患の治療用の、局所用Ｒ，Ｒ-グリコピロレート、又はその生理学的に許容される塩とホスホジエステラーゼ(ＰＤＥ)４阻害剤、又はその生理的に許容される塩との組合せ剤。
- 前記ホスホジエステラーゼ(ＰＤＥ)４阻害剤が、ロフルミラスト、ロリプラム若しくはＡＷＤ１２−２８１、又はそれらの生理学的に許容される塩を含む群から選ばれる、請求項１に記載の組合せ剤。
- 前記ホスホジエステラーゼ(ＰＤＥ)４阻害剤が、ロフルミラスト又はその生理学的に許容される塩である、請求項２に記載の組合せ剤。
- 前記ホスホジエステラーゼ(ＰＤＥ)４阻害剤が、ＡＷＤ１２-２８１又はその生理学的に許容される塩である、請求項２に記載の組合せ剤。
- 前記Ｒ,Ｒ-グリコピロレートの一日用量が、５〜５００μｇ、好ましくは１５〜３００μｇであり、そしてＰＤＥ４阻害剤の一日用量が、２００〜５０００μｇ／日、好ましくは５００〜２０００μｇ／日である、請求項１〜４のいずれか一項に記載の組合せ剤。
- Ｒ,Ｒ-グリコピロレートの一日用量が、５〜１００μｇであり、そしてＰＤＥ４阻害剤の一日用量が２００〜５０００μｇ／日、好ましくは５００〜２０００μｇ／日である、請求項１〜４のいずれか一項に記載の組合せ剤。
- 局所用Ｒ,Ｒ-グリコピロレート又はその生理学的に許容される塩及び少なくとも１の４型ホスホジエステラーゼ阻害剤又はその生理学的に許容される塩を含む、喘息又は呼吸器系疾患の治療用医薬品。
- 前記２個の活性物質が、吸入されたときに適切な粒子サイズ分散で利用できることを特徴とする、請求項７に記載の医薬品。
- 前記医薬品が、噴霧剤を伴うか又は伴わない吸入可能エアロゾルであることを特徴とする、請求項７に記載の医薬品。
- 前記医薬品が、吸入可能な乾燥粉末であることを特徴とする、請求項７に記載の医薬品。
- 前記医薬品が、吸入可能な懸濁液又は溶液であることを特徴とする、請求項７に記載の医薬品。
- 吸入器内にＲ，Ｒグリコピロレート、又はその生理学的に許容される塩、及び少なくとも１の４型ホスホジエステラーゼの阻害剤又はその生理学的に許容される塩を含む、請求項７〜１１のいずれか一項に記載の医薬品。
- Ｒ,Ｒグリコピロレート及びＡＷＤ１２−２８１、或いはそれらの生理学的に許容される塩を含む、請求項１２に記載の医薬品。
- Ｒ,Ｒグリコピロレート及びロフルミラスト、或いはそれらの生理学的に許容される塩を含む、請求項１２に記載の医薬品。
- 前記活性物質が、吸入適用に適した医薬形態中で、通常の賦形剤、補助剤、及び添加剤を伴って同時に、連続して、又は別々に投与するために、固定された又は自由な組合せで存在することを特徴とする、請求項７〜１４のいずれか一項に記載の医薬品。
- 哺乳動物における喘息／アレルギー及び／又は呼吸器系疾患の治療用の、局所用Ｒ，Ｒグリコピロレート又はその生理学的に許容される塩と少なくとも１の４型ホスホジエステラーゼ阻害剤又はそれらの生理学的に許容される塩との組合せ剤。
- 前記哺乳動物がヒト又はウマである、請求項１６に記載の組合わせ剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54195504P | 2004-02-06 | 2004-02-06 | |
| US60/541,955 | 2004-02-06 | ||
| PCT/EP2005/000651 WO2005074982A2 (en) | 2004-02-06 | 2005-01-24 | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007520507A JP2007520507A (ja) | 2007-07-26 |
| JP2007520507A5 true JP2007520507A5 (ja) | 2007-12-27 |
| JP4700014B2 JP4700014B2 (ja) | 2011-06-15 |
Family
ID=34837532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551762A Expired - Fee Related JP4700014B2 (ja) | 2004-02-06 | 2005-01-24 | 呼吸器系疾患の治療用の抗コリン作用薬及び４型ホスホジエステラーゼの組合せ剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20050175547A1 (ja) |
| EP (1) | EP1713471B1 (ja) |
| JP (1) | JP4700014B2 (ja) |
| CN (2) | CN101518532A (ja) |
| AT (1) | ATE541570T1 (ja) |
| AU (1) | AU2005210084B2 (ja) |
| CA (1) | CA2550848C (ja) |
| CY (1) | CY1112968T1 (ja) |
| DK (1) | DK1713471T3 (ja) |
| ES (1) | ES2381116T3 (ja) |
| HK (1) | HK1096311A1 (ja) |
| HR (1) | HRP20120286T1 (ja) |
| NO (1) | NO337023B1 (ja) |
| NZ (1) | NZ548301A (ja) |
| PL (1) | PL1713471T3 (ja) |
| PT (1) | PT1713471E (ja) |
| RU (1) | RU2437658C2 (ja) |
| SI (1) | SI1713471T1 (ja) |
| WO (1) | WO2005074982A2 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| EP1720543A1 (en) * | 2004-02-27 | 2006-11-15 | Altana Pharma AG | Roflumilast and glycopryrronium combination |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| AU2006305619A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of muscarinic receptor antagonists |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| RU2470639C2 (ru) * | 2007-10-25 | 2012-12-27 | Мерк Фросст Кэнада Лтд. | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид |
| CA2716936C (en) * | 2008-02-26 | 2018-06-05 | Elevation Pharmaceuticals, Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| US9649302B2 (en) * | 2013-01-28 | 2017-05-16 | Incozen Therapeutics Pvt. Ltd. | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide |
| LT2968313T (lt) * | 2013-03-15 | 2018-05-10 | Verona Pharma Plc | Vaistų derinys |
| TW201542207A (zh) * | 2013-10-03 | 2015-11-16 | Otsuka Pharma Co Ltd | 嚴重氣喘治療劑 |
| CN104586841A (zh) * | 2013-10-30 | 2015-05-06 | 中国药科大学 | (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途 |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| RU2691110C2 (ru) * | 2017-11-20 | 2019-06-11 | Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) | Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100331255B1 (ko) * | 1993-07-02 | 2002-10-25 | 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 | 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도 |
| US6204285B1 (en) * | 1996-07-01 | 2001-03-20 | Sepracor Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate |
| US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| AU7455498A (en) * | 1998-05-29 | 1999-12-20 | Citizen Watch Co. Ltd. | Method of subjecting ink jet printer to preuse treatment |
| US6475467B1 (en) | 1998-08-04 | 2002-11-05 | Jago Research Ag | Medicinal aerosol formulations |
| EP1131059B1 (de) | 1998-11-13 | 2003-03-05 | Jago Research Ag | Trockenpulver zur inhalation |
| US6086914A (en) | 1999-03-12 | 2000-07-11 | Weinstein; Robert E. | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US20040002548A1 (en) | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| US20040028958A1 (en) | 2002-06-18 | 2004-02-12 | Total Innovative Manufacturing Llc | Recyclable fire-resistant moldable batt and panels formed therefrom |
| DE19961300A1 (de) | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| DE10007203A1 (de) | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0029903D0 (en) | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
| HU229798B1 (en) | 2001-03-30 | 2014-07-28 | Jagotec Ag | Medical aerosol compositions and process for their preparation |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| CN1511042A (zh) * | 2001-05-25 | 2004-07-07 | 治疗阻塞性气道疾病的pde4抑制剂与抗胆碱能剂的组合 | |
| MXPA03010791A (es) * | 2001-05-25 | 2004-03-02 | Boehringer Ingelheim Pharma | Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias. |
| GB0118373D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20040038958A1 (en) * | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| UA82323C2 (uk) | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| WO2004023984A2 (en) | 2002-09-13 | 2004-03-25 | Smith C Steven | Novel composition and method for treatment of upper respiratory conditions |
| DK1610787T3 (da) * | 2003-03-28 | 2008-06-02 | Nycomed Gmbh | Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme |
| WO2004084897A1 (en) | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| EP1646881A1 (en) | 2003-07-11 | 2006-04-19 | Philips Intellectual Property & Standards GmbH | Improved frequency determination |
-
2005
- 2005-01-24 PT PT05701141T patent/PT1713471E/pt unknown
- 2005-01-24 WO PCT/EP2005/000651 patent/WO2005074982A2/en active Application Filing
- 2005-01-24 PL PL05701141T patent/PL1713471T3/pl unknown
- 2005-01-24 ES ES05701141T patent/ES2381116T3/es active Active
- 2005-01-24 EP EP05701141A patent/EP1713471B1/en active Active
- 2005-01-24 RU RU2006132040/15A patent/RU2437658C2/ru not_active Application Discontinuation
- 2005-01-24 CN CN200910133531A patent/CN101518532A/zh active Pending
- 2005-01-24 CA CA2550848A patent/CA2550848C/en not_active Expired - Fee Related
- 2005-01-24 NZ NZ548301A patent/NZ548301A/en unknown
- 2005-01-24 SI SI200531513T patent/SI1713471T1/sl unknown
- 2005-01-24 AU AU2005210084A patent/AU2005210084B2/en not_active Ceased
- 2005-01-24 JP JP2006551762A patent/JP4700014B2/ja not_active Expired - Fee Related
- 2005-01-24 CN CNB200580002345XA patent/CN100512813C/zh not_active Expired - Fee Related
- 2005-01-24 DK DK05701141.3T patent/DK1713471T3/da active
- 2005-01-24 AT AT05701141T patent/ATE541570T1/de active
- 2005-02-07 US US11/051,463 patent/US20050175547A1/en not_active Abandoned
-
2006
- 2006-07-13 US US11/485,486 patent/US20060251589A1/en not_active Abandoned
- 2006-08-31 NO NO20063880A patent/NO337023B1/no not_active IP Right Cessation
-
2007
- 2007-04-11 HK HK07103735.7A patent/HK1096311A1/xx not_active IP Right Cessation
-
2009
- 2009-02-03 US US12/365,003 patent/US8097605B2/en active Active
-
2012
- 2012-03-29 CY CY20121100323T patent/CY1112968T1/el unknown
- 2012-03-30 HR HR20120286T patent/HRP20120286T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520507A5 (ja) | ||
| Weers et al. | The impact of inspiratory flow rate on drug delivery to the lungs with dry powder inhalers | |
| RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
| JP2007520508A5 (ja) | ||
| Dolovich et al. | Aerosol drug delivery: developments in device design and clinical use | |
| RU2006132040A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| JP2007520506A5 (ja) | ||
| Westerman et al. | Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study | |
| RU2006132038A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| HRP20160373T1 (hr) | Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava | |
| JP2008533072A5 (ja) | ||
| CA2558212A1 (en) | Interferon-beta for anti-virus therapy for respiratory diseases | |
| NO20064161L (no) | Farmasoytiske formuleringer for torrpulverinhalatorer omfattende en aktiv ingrediens med lavdoseringsstyrke | |
| JP2008518007A5 (ja) | ||
| BR0317443A (pt) | Medicamento pulverulento para inalação contendo um sal de tiotrópio e xinafoato de salmeterol | |
| JP2014514271A5 (ja) | ||
| Wallin et al. | Pulmonary drug delivery to older people | |
| EA200701077A1 (ru) | Применение конъюгатов липидов при лечении заболеваний | |
| CN103476412B (zh) | 用于改善呼吸系统疾病患者睡眠质量的阿地铵 | |
| SK2302003A3 (en) | Pharmaceutical formulation of salmeterol and fluticasone propionate | |
| HK1078795A1 (en) | Powder formulations suitable for inhalation | |
| Debnath et al. | Status of inhalable antimicrobial agents for lung infection: progress and prospects | |
| US20150250779A1 (en) | Agent for Ameliorating Chronic Obstructive Pulmonary Disease | |
| BR0316343A (pt) | Formulações pulverulentas para inalação contendo tiotrópio |